Top Markets
Coin of the day
Lisata Therapeutics, Inc. Lisata Therapeutics, Inc.

Lisata Therapeutics, Inc.

LSTA
Rank in Stocks #32451
Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on... Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on pioneering and bringing to market cellular therapies. These treatments are designed to either reverse disease progression or facilitate the repair of damaged bodily tissues. The company's product portfolio features several notable candidates: HONEDRA, which has received SAKIGAKE designation and is presently in Phase II clinical trials for critical limb ischemia; XOWNA, currently undergoing Phase IIb testing for coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy aimed at individuals with chronic kidney disease who are not yet on dialysis. Founded in 1980 and based in Basking Ridge, New Jersey, the company was initially known as NeoStem, Inc., then rebranded as Caladrius Biosciences, Inc. in June 2015, before assuming its present identity as Lisata Therapeutics, Inc. on September 15, 2022.
Share Price
$1.11
Market Cap
$10.06M
Change (1 day)
1.38%
Change (1 year)
-56.32%
Country
US
Trade Lisata Therapeutics, Inc. (LSTA)

Category

Dividend yield history for Lisata Therapeutics, Inc. (LSTA)
Lisata Therapeutics, Inc. (stock symbol: LSTA) dividend yield (TTM) as of 2026: 0
Average dividend yield, last 5 years : 0.00%
Dividend yield history for Lisata Therapeutics, Inc. (LSTA) from 2026 to 2026
Dividend Yield at the end of each year (TTM)
Year Dividend Yield Change
Not enough data for the provided dates.
Dividend yields (TTM) for similar companies or competitors